Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,301 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,832 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00088868 | 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma | completed | Phase 1 | 40 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 15, 2012 | clinicaltrials |
| NCT00132015 | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis | completed | Phase 2 | 37 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 15, 2012 |
| clinicaltrials |
| NCT00281801 | Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow Transplantation | completed | — | 168 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 15, 2012 | clinicaltrials |
| NCT00387608 | ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer | completed | Phase 1 | 23 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 15, 2012 | clinicaltrials |
| NCT00430053 | Clinical Evaluations and Laboratory Studies to Study the Disease Course in Patients With Cutaneous T-Cell Lymphoma | completed | — | 100 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 15, 2012 | clinicaltrials |
| NCT00211276 | A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma | completed | Phase 2 | 50 | Eisai Inc.INDUSTRY | 1 | Mar 14, 2012 | clinicaltrials |
| NCT00064311 | Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation | completed | Phase 1 / Phase 2 | — | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 8, 2012 | clinicaltrials |
| NCT00080925 | T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies | completed | Phase 1 | 20 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 8, 2012 | clinicaltrials |
| NCT00146614 | Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation | completed | Phase 2 | 105 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 8, 2012 | clinicaltrials |
| NCT00589381 | Fenretinide Lym-X-Sorb™ in Treating Patients With Recurrent or Resistant Solid Tumors or Lymphoma | completed | Phase 1 | 30 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 8, 2012 | clinicaltrials |
| NCT00945828 | Assessing the Effectiveness of Individual Education Plans for Childhood Cancer Survivors | completed | N/A | 62 | University of MiamiOTHER | 1 | Mar 8, 2012 | clinicaltrials |
| NCT00799461 | Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications | completed | Phase 3 | 1,337 | Fred Hutchinson Cancer Research Center/University of Washington Cancer ConsortiumOTHER | 1 | Mar 7, 2012 | clinicaltrials |
| NCT00499759 | Individualized Exercise Programs for Patients Receiving Chemotherapy for Newly Diagnosed Acute or Relapsed Myeloid Leukemia or Lymphoblastic Leukemia | completed | N/A | 10 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Mar 6, 2012 | clinicaltrials |
| NCT00581737 | Cognitive Functioning and Quality of Life in CNS Lymphoma | completed | — | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 5, 2012 | clinicaltrials |
| NCT00101660 | Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib | completed | Phase 2 | 387 | Bristol-Myers SquibbINDUSTRY | 22 | Mar 2, 2012 | clinicaltrials |
| NCT00506857 | Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support | completed | Phase 1 / Phase 2 | 82 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 28, 2012 | clinicaltrials |
| NCT01147991 | Vaccine Therapy in Treating Patients With Epstein-Barr Virus-Related Cancer | completed | Phase 1 | 16 | Cancer Research UKOTHER | 1 | Feb 28, 2012 | clinicaltrials |
| NCT00432562 | A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion in Patients With Advanced Cancer. | completed | Phase 1 | 31 | Mast Therapeutics, Inc.INDUSTRY | 1 | Feb 23, 2012 | clinicaltrials |
| NCT00018954 | Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma | completed | Phase 2 | — | National Institutes of Health Clinical Center (CC)NIH | 3 | Feb 20, 2012 | clinicaltrials |
| NCT00489632 | Children's Resiliency, Adjustment, and Coping | completed | — | 66 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 20, 2012 | clinicaltrials |
| NCT00493181 | Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients | completed | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 20, 2012 | clinicaltrials |
| NCT00568815 | Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL) | completed | Phase 2 | 31 | Fudan UniversityOTHER | 1 | Feb 20, 2012 | clinicaltrials |
| NCT00854425 | L-asparaginase Monotherapy as Salvage Treatment in Patients With NK/T Cell Lymphoma | completed | Phase 2 | 40 | Fudan UniversityOTHER | 1 | Feb 20, 2012 | clinicaltrials |
| NCT00890656 | Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage | completed | Phase 2 | 90 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 20, 2012 | clinicaltrials |
| NCT01082939 | Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 20, 2012 | clinicaltrials |
| NCT00764829 | Blood Samples to Evaluate Biomarkers of Donor Chimerism | completed | — | 80 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2012 | clinicaltrials |
| NCT00549185 | Multi-dose-escalation Safety and Pharmacokinetic Study of SAR3419 as Single Agent in Relapsed/Refractory B-cell Non Hodgkin's Lymphoma | completed | Phase 1 | 39 | SanofiINDUSTRY | 1 | Feb 14, 2012 | clinicaltrials |
| NCT00289549 | Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 8 | BioCryst PharmaceuticalsINDUSTRY | 1 | Feb 8, 2012 | clinicaltrials |
| NCT00493129 | Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM) | completed | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 8, 2012 | clinicaltrials |
| NCT00764231 | A Study of a Home-based Exercise Intervention for Patients With Acute Myeloid Leukaemia (AML) | completed | Phase 2 | 40 | Toronto Rehabilitation InstituteOTHER | 1 | Feb 8, 2012 | clinicaltrials |
| NCT00116961 | Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma | completed | Phase 2 | 40 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 7, 2012 | clinicaltrials |
| NCT00135187 | Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma | completed | N/A | 30 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 7, 2012 | clinicaltrials |
| NCT01527422 | Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab Pateinets With Aggresive NHL(CHOP-R) | completed | Phase 1 / Phase 2 | 60 | Fernando CabanillasOTHER | 1 | Feb 7, 2012 | clinicaltrials |
| NCT00029224 | Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions | completed | Phase 4 | 500 | NovartisINDUSTRY | 1 | Feb 1, 2012 | clinicaltrials |
| NCT00143871 | Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma | completed | Phase 2 | 35 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 1, 2012 | clinicaltrials |
| NCT00608907 | An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib) | completed | Phase 1 | 61 | Millennium Pharmaceuticals, Inc.INDUSTRY | 5 | Jan 30, 2012 | clinicaltrials |
| NCT00144677 | Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation | completed | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 26, 2012 | clinicaltrials |
| NCT00144703 | Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation | completed | Phase 2 | 55 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 26, 2012 | clinicaltrials |
| NCT00286845 | Use of the MiCK Assay for Apoptosis in AML | completed | — | 50 | Pierian BiosciencesINDUSTRY | 1 | Jan 26, 2012 | clinicaltrials |
| NCT00531453 | A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 98 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 26, 2012 | clinicaltrials |
| NCT01517581 | Brown Fat Activity and White Fat Accumulation | completed | — | 32 | Children's Hospital Los AngelesOTHER | 1 | Jan 25, 2012 | clinicaltrials |
| NCT00042250 | IUdR/BUdR Cell Cycle Labelling | completed | N/A | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 24, 2012 | clinicaltrials |
| NCT00423709 | Allogeneic Blood Stem Cell Transplantation | completed | N/A | 46 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 24, 2012 | clinicaltrials |
| NCT00640523 | Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 23 | BioCryst PharmaceuticalsINDUSTRY | 2 | Jan 23, 2012 | clinicaltrials |
| NCT00795548 | Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation | completed | Phase 2 | 30 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Jan 23, 2012 | clinicaltrials |
| NCT00088231 | PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP | completed | Phase 1 / Phase 2 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 20, 2012 | clinicaltrials |
| NCT00289562 | Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 20 | BioCryst PharmaceuticalsINDUSTRY | 1 | Jan 20, 2012 | clinicaltrials |
| NCT00095381 | Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia | completed | Phase 2 | 20 | BioCryst PharmaceuticalsINDUSTRY | 2 | Jan 19, 2012 | clinicaltrials |
| NCT00427765 | Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple Myeloma | completed | Phase 2 | 168 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 19, 2012 | clinicaltrials |
| NCT00048230 | PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 3 | 620 | Millennium Pharmaceuticals, Inc.INDUSTRY | 13 | Jan 13, 2012 | clinicaltrials |
Data updated 24 days agoSource updated Mar 15, 2012source: clinicaltrials